Literature DB >> 6250809

Angiotensin-converting enzyme: I. New strategies for assay.

J W Ryan, A Chung, U S Ryan.   

Abstract

The disposition of converting enzyme (kininase II) on the luminal surface of pulmonary endothelial cells is well established. Further, it is known that there is a net conversion of angiotensin I into angiotensin II as blood passes through the lungs. However, little is known about modulations of converting enzyme activity that may arise through, e.g., changes in the quality of inhalants, blood flow, or blood oxygenation. There are few data on the effects of lung disease. A major barrier to studies to examine for pathophysiologic modulations of converting enzyme is that of assay. The enzyme can be measured in terms of the rate of formation of angiotensin II from a known quantity of angiotensin I. However, both peptides are biologically active, and lungs contain other enzymes capable of degrading them. We have developed a series of radiolabeled, acylated tripeptides to improve our ability to examine for changes in the net converting enzyme of intact lungs. The enzyme, a dipeptidyl carboxypeptidase, is capable of removing C-terminal dipeptides from a variety of oligopeptides. We have prepared benzoyl-Gly-Gly-Gly (I), benzoyl-Pro-Phe-Arg (II), benzoyl-Gly-His-Leu (III), benzoyl-Phe-Ala-Pro (IV), and benzoyl-Phe-His-Leu (V), each containing a (3)H-atom in the para position of the benzoyl moiety. Substrates I and III have been used previously in photometric assays of low sensitivity. II is the acylated C-terminal tripeptide of bradykinin, IV is an acylated tripeptide analog of BPP(5a) (<Glu-Lys-Trp-Ala-Pro) and V is the acylated C-terminal tripeptide of angiotensin I. These substrates can be used in vitro or in vivo to measure converting enzyme. The (3)H-labeled product is separable by partitioning between an organic solvent and acidified aqueous solution. The product is quantified by scintillation counting of the organic phase. The choice of substrate depends on the goals of the experiment: substrate I or III when wide variations in substrate concentrations are needed but high sensitivity is not; substrate IV when high sensitivity is needed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6250809      PMCID: PMC1568461          DOI: 10.1289/ehp.8035165

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  22 in total

1.  Kinetic properties of pulmonary angiotensin-converting enzyme. Hydrolysis of hippurylglycylglycine.

Authors:  F E Dorer; J R Kahn; K E Lentz; M Levine; L T Skeggs
Journal:  Biochim Biophys Acta       Date:  1976-03-11

2.  Subcellular localization of pulmonary antiotensin-converting enzyme (kininase II).

Authors:  J W Ryan; U S Ryan; D R Schultz; C Whitaker; A Chung
Journal:  Biochem J       Date:  1975-02       Impact factor: 3.857

3.  Hydrolysis of bradykinin by angiotensin-converting enzyme.

Authors:  F E Dorer; J R Kahn; K E Lentz; M Levine; L T Skeggs
Journal:  Circ Res       Date:  1974-06       Impact factor: 17.367

4.  Inhibition of angiotensin-coverting enzyme by analogs of peptides from Bothrops jararaca venom.

Authors:  D W Cushman; J Pluscec; N J Williams; E R Weaver; E F Sabo; O Kocy; H S Cheung; M A Ondetti
Journal:  Experientia       Date:  1973-08-15

5.  Purification and properties of angiotensin-converting enzyme from hog lung.

Authors:  F E Dorer; J R Kahn; K E Lentz; M Levine; L T Skeggs
Journal:  Circ Res       Date:  1972-09       Impact factor: 17.367

6.  Metabolism of [8-L-[14C] phenylalanine]-angiotensin I in the pulmonary circulation.

Authors:  J W Ryan; R S Niemeyer; D W Goodwin; U Smith
Journal:  Biochem J       Date:  1971-12       Impact factor: 3.857

7.  Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis.

Authors:  M A Ondetti; N J Williams; E F Sabo; J Pluscec; E R Weaver; O Kocy
Journal:  Biochemistry       Date:  1971-10-26       Impact factor: 3.162

8.  Hydrolysis of bradykinin and its higher homologues by angiotensin-converting enzyme.

Authors:  F Dorer; J W Ryan; J M Stewart
Journal:  Biochem J       Date:  1974-09       Impact factor: 3.857

9.  Angiotensin-converting enzyme: vascular endothelial localization.

Authors:  P R Caldwell; B C Seegal; K C Hsu; M Das; R L Soffer
Journal:  Science       Date:  1976-03-12       Impact factor: 47.728

10.  Angiotensin I: metabolism by plasma membrane of lung.

Authors:  J W Ryan; U Smith; R S Niemeyer
Journal:  Science       Date:  1972-04-07       Impact factor: 47.728

View more
  3 in total

Review 1.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

2.  Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit and coronary microvessels and isolated and cultivated coronary microvessel endothelial cells.

Authors:  M E Gerritsen; C D Cheli
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

3.  Transpulmonary pharmacokinetics of an ACE inhibitor (perindoprilat) in man.

Authors:  R J MacFadyen; K R Lees; J D Gemmill; W S Hillis; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.